IL254766B - A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome - Google Patents

A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome

Info

Publication number
IL254766B
IL254766B IL254766A IL25476617A IL254766B IL 254766 B IL254766 B IL 254766B IL 254766 A IL254766 A IL 254766A IL 25476617 A IL25476617 A IL 25476617A IL 254766 B IL254766 B IL 254766B
Authority
IL
Israel
Prior art keywords
sjogren
trifluoroethyl
syndrome
treatment
specific
Prior art date
Application number
IL254766A
Other languages
English (en)
Hebrew (he)
Other versions
IL254766A0 (en
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of IL254766A0 publication Critical patent/IL254766A0/en
Publication of IL254766B publication Critical patent/IL254766B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL254766A 2015-04-21 2017-09-28 A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome IL254766B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (2)

Publication Number Publication Date
IL254766A0 IL254766A0 (en) 2017-12-31
IL254766B true IL254766B (en) 2020-05-31

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254766A IL254766B (en) 2015-04-21 2017-09-28 A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2612862T (lt) * 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
HRP20160350T1 (hr) * 2007-03-23 2016-05-06 Amgen Inc. Heterociklički spojevi i njihove uporabe
LT2496567T (lt) * 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2667173T3 (es) * 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa

Also Published As

Publication number Publication date
AU2016251236A1 (en) 2017-11-09
EA032432B1 (ru) 2019-05-31
CY1122572T1 (el) 2021-01-27
CA2981631C (en) 2023-02-21
ES2763335T3 (es) 2020-05-28
SG11201707789YA (en) 2017-11-29
JP6721606B2 (ja) 2020-07-15
EA201792318A1 (ru) 2018-05-31
HRP20192273T1 (hr) 2020-03-06
US10493074B2 (en) 2019-12-03
EP3285772B1 (en) 2019-10-02
KR102627370B1 (ko) 2024-01-18
PL3285772T3 (pl) 2020-05-18
BR112017020591B8 (pt) 2023-05-16
LT3285772T (lt) 2020-01-10
CO2017010573A2 (es) 2018-03-09
KR20170140245A (ko) 2017-12-20
SI3285772T1 (sl) 2020-02-28
HUE047162T2 (hu) 2020-04-28
EP3285772A1 (en) 2018-02-28
AU2016251236B2 (en) 2018-06-14
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
MX2017013148A (es) 2018-02-21
CL2017002669A1 (es) 2018-05-11
GB201506786D0 (en) 2015-06-03
WO2016170014A1 (en) 2016-10-27
BR112017020591A2 (pt) 2018-07-03
PT3285772T (pt) 2020-01-14
US20180092921A1 (en) 2018-04-05
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20
BR112017020591B1 (pt) 2023-02-07
JP2018513862A (ja) 2018-05-31
CA2981631A1 (en) 2016-10-27
AR105552A1 (es) 2017-10-18
DK3285772T3 (da) 2020-01-13

Similar Documents

Publication Publication Date Title
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL262943A (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
EP3130582A4 (en) Novel compound having immune disease treatment effect and use thereof
GB2538923B (en) A therapeutic agent for use in the treatment of infections
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
IL254766A0 (en) A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
ME03660B (me) Derivati aminohidroziazina kondenzirani s tetrahidrofuranom, korisni u liječenju alzheimerove bolesti
PL3229780T3 (pl) Kompozycje okulistyczne do zastosowania w leczeniu zespołu suchego oka
GB201513543D0 (en) Compositions for use in the treatment of diabetes
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201412638D0 (en) Artist's implement
AU2014902872A0 (en) Bowler's arm
AU2014901914A0 (en) Bowler's arm
GB201500543D0 (en) The Edward's chronometer
GB201518052D0 (en) Parkinson's disease treatment
ZA201408464B (en) Composition for the use in treatment of asthma
GB201513919D0 (en) Effiena's handmade polish

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed